Hillstar Bio, a leading biotechnology company focused on developing next-generation precision immunology therapies for autoimmune diseases, today announced the successful closing of a $67 million Series A financing round. This funding was led by a syndicate of experienced investors and shareholders from the U.S., Europe, and Asia, including Droia Ventures, Frazier Life Sciences, Novo Holdings A/S, LifeArc Ventures, and Hummingbird Bioscience..

Hillstar Bio是一家领先的生物技术公司，专注于开发用于自身免疫性疾病的下一代精准免疫疗法，今天宣布成功完成了6700万美元的A轮融资。本轮融资由来自美国、欧洲和亚洲的经验丰富的投资者和股东牵头，包括Droia Ventures、Frazier Life Sciences、Novo Holdings A/S、LifeArc Ventures和Hummingbird Bioscience。

Hillstar Bio is ushering in a new era in autoimmune disease treatment through precision immunology. The company selectively targets and depletes pathogenic immune cells while sparing healthy ones, offering the potential for durable relief and immune reset for patients with autoimmune conditions. Unlike traditional therapies that broadly suppress the immune system, Hillstar Bio's targeted approach addresses specific disease mechanisms by eliminating the underlying source and reducing the risks associated with chronic broad immunosuppression.

Hillstar Bio正通过精准免疫学开创自身免疫疾病治疗的新时代。该公司选择性地靶向并清除致病的免疫细胞，同时保留健康细胞，为自身免疫疾病患者提供了持久缓解和免疫系统重置的潜力。与传统疗法广泛抑制免疫系统不同，Hillstar Bio的靶向方法通过消除根本病因来应对特定疾病机制，同时降低了长期广泛免疫抑制带来的风险。

=.

=。